Teva Wins U.S. Approval to Buy Actavis After Selling Generics

The U.S. Federal Trade Commission approved Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generic drug-making unit after the companies agreed to divest certain drugs to preserve competition in the pharmaceutical market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.